Erythropoietin alpha

DRUG3 trials

Sponsors

Mathew S. Maurer, Novartis Pharmaceuticals, Globe Biotech Limited

Conditions

AnemiaLow and Int 1-risk Myelodysplastic SyndromeNatural Blood and Blood Product Toxicity

Phase 1

A Randomized, Double-blinded, Active Controlled Crossover Clinical Trial to Investigate PK, PD and Safety of GBPD002

CompletedNCT05585658

Globe Biotech LimitedNatural Blood and Blood Product Toxicity

Start: 2021-10-16End: 2021-12-16Updated: 2022-10-20

Phase 2

Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)

CompletedNCT00286182

Mathew S. MaurerAnemia

Start: 2007-07-31End: 2012-11-30Updated: 2017-03-10

Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

CompletedNCT01868477

Novartis PharmaceuticalsLow and Int 1-risk Myelodysplastic Syndrome

Start: 2014-01-28End: 2017-04-05Updated: 2018-10-31

Related Papers

Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial.

2018-05-191 citations

Impact of epoetin alfa on left ventricular structure, function, and pressure volume relations as assessed by cardiac magnetic resonance: the heart failure preserved ejection fraction (HFPEF) anemia trial.

2013-03-203 citations

Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy.

2012-12-2036 citations